May 23 (Reuters) - Gilead Sciences Inc GILD.O:
ASCENT-03: TRODELVY® DEMONSTRATES HIGHLY STATISTICALLY SIGNIFICANT & CLINICALLY MEANINGFUL IMPROVEMENT IN PROGRESSION FREE SURVIVAL IN PATIENTS WITH FIRST-LINE METASTATIC TRIPLE-NEGATIVE BREAST CANCER WHO ARE NOT CANDIDATES FOR CHECKPOINT INHIBITORS
GILEAD SCIENCES INC - ASCENT-03 STUDY MEETS PRIMARY ENDPOINT WITH SIGNIFICANT IMPROVEMENT IN PFS
GILEAD SCIENCES INC - TRODELVY SAFETY PROFILE CONSISTENT WITH PRIOR STUDIES IN ASCENT-03
GILEAD SCIENCES INC - NO OS DETRIMENT OBSERVED IN ASCENT-03 STUDY
Source text: ID:nBw6DGjPHa
Further company coverage: GILD.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.